CONMED Corp.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US2074101013

USD

44.24

-0.11 (-0.25%)

Dec 04

NYS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Globus Medical, Inc.

Glaukos Corp.

Sotera Health Co.

Sanmina Corp.

Neogen Corp.

Merit Medical Systems, Inc.

Haemonetics Corp.

Envista Holdings Corp.

CONMED Corp.

Integra LifeSciences Holdings Corp.

Inari Medical, Inc.

Why is CONMED Corp. ?

Poor long term growth as Operating profit has grown by an annual rate 18.38% of over the last 5 years

The company has declared negative results in Mar'2025 after 3 consecutive positive quarters

NET PROFIT(HY) At USD 27.05 MM has Grown at -45.97%

Below par performance in long term as well as near term

Along with generating -40.05% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CONMED Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

CONMED Corp.

-40.05%

-0.96

42.37%

S&P 500

13.22%

0.65

20.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.88%

EBIT Growth (5y)

18.38%

EBIT to Interest (avg)

3.03

Debt to EBITDA (avg)

5.39

Net Debt to Equity (avg)

0.88

Sales to Capital Employed (avg)

0.67

Tax Ratio

18.26%

Dividend Payout Ratio

18.82%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

6.55%

ROE (avg)

7.82%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.92

EV to EBIT

19.37

EV to EBITDA

13.82

EV to Capital Employed

1.49

EV to Sales

2.09

PEG Ratio

9.49

Dividend Yield

130.84%

ROCE (Latest)

7.70%

ROE (Latest)

9.11%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at 84.55 %

RAW MATERIAL COST(Y)

Fallen by -0.53% (YoY

-3What is not working for the Company

NET PROFIT(HY)

At USD 27.05 MM has Grown at -45.97%

Here's what is working for CONMED Corp.

Debt-Equity Ratio

Lowest at 84.55 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -0.53% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CONMED Corp.

Net Profit

At USD 27.05 MM has Grown at -45.97%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)